Mitochondrial DNA-Targeting Conjugates for Mutant Copy Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and efficient way to target and treat mitochondrial DNA mutations, which are associated with diseases such as mitochondrial disease, lifestyle-related diseases, and cancer, particularly in cases of homoplasmy where all mitochondrial DNA has a mutation, and existing compounds like hairpin pyrrole-imidazole polyamide are not suitable for drug development due to high molecular weight and complex synthesis.
Innovation Solution
A conjugate of a low-molecular-weight linear compound that binds to the DNA minor groove and a lipophilic cation, such as TPP, is developed to specifically target mitochondrial DNA, inducing mitochondrial autophagy, reducing mutant DNA copy numbers, and promoting cell death in cells with homoplasmy or high mutant DNA content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hairpin pyrrole-imidazole polyamide is used to target mitochondrial DNA, then biological activity is achieved, but molecular weight is high and synthesis is complex
Solution Approach 1:
The patent segments the original hairpin pyrrole-imidazole polyamide into a simpler linear compound structure that retains DNA binding capability while reducing molecular complexity and synthesis difficulty
Solution Approach 2:
The patent extracts the essential DNA binding function from the complex hairpin structure and implements it through a simplified linear compound with reduced molecular weight and easier synthesis pathway
2Reliability
If conventional DNA targeting compounds are used, then DNA binding is achieved, but mitochondrial retention is insufficient
Solution Approach 1:
The patent merges two functional components into a single conjugate: a DNA binding compound for sequence-specific recognition and a lipophilic cation for mitochondrial targeting and retention, achieving both DNA binding and prolonged mitochondrial presence
Solution Approach 2:
The lipophilic cation acts as an intermediary that facilitates mitochondrial accumulation and retention of the DNA binding compound, enabling the compound to remain in mitochondria long enough to exert biological activity
3Reliability
If mitochondrial DNA mutation is present, then disease pathology is established, but effective treatment method is lacking
Solution Approach 1:
The patent changes the therapeutic approach by using a small molecule conjugate with specific physicochemical parameters (lipophilic cation + DNA binding compound) that can penetrate mitochondria and selectively target mutant DNA, making treatment feasible for previously untreatable conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate effectively decreases mutant mitochondrial DNA copy numbers, induces mitochondrial autophagy, and promotes cell death in cells with high mutant DNA content, offering a potential radical therapeutic approach for mitochondrial-related diseases and cancer, with applications in both animal and plant cells.
Implementation Method 1
Lipophilic cations and the like have been developed as techniques of delivering drugs to double-membrane organelles such as mitochondria
Implementation Method 2
a low-molecular-weight linear compound that binds to a DNA minor groove
Data Source
Figure 1-1
Figure 1-2
Figure 2A~2B
AI summary
The present invention provides a drug for a pathological condition including mitochondria-related disease by a conjugate of a double-membrane organelle DNA sequence recognizing compound and a double-membrane organelle localizable compound. The present invention provides a conjugate in which a double-membrane organelle localizable lipophilic cation is attached to linear PI polyamide that specifically binds to a double-membrane organelle DNA sequence, a linear PI polyamide-TPP conjugate targeting the mitochondrial DNA mutation or polymorphism, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.